Innovo Mimetics

Chick Egg Assay System for Cancer Therapies

Health Tech & Life Sciences
Non Active, Dec 2024 ceased to operate
Seed Jerusalem, Israel Founded 2010
Last updated 2026-06-18
Total raised
$160K
Last: Grant 2017-08
Stage
Seed
Founded
2010
Headcount
8
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences

About

Innovo Mimetics specializes in anti-cancer therapy efficacy assays in the well-established chick egg tumor xenograft model. This model is based on the ability of a fertilized chick egg to engraft and nourish foreign cells, including cancer cells, that are placed in the egg. Innovo's proprietary assay system, ScreenOvo, allows rapid and low-cost evaluation of chemical, biological, and cell therapies. The advantages of the ScreenOvo Assay include a living tumor at low cost; a complete assay in 14 days; and broad applicability for testing immune cell therapies, checkpoint inhibition, and anti-cancer drug efficacy. ScreenOvo is designed as a service tool for immunotherapy and pharmaceutical companies to deliver xenograft tumor data in the chick egg model in order to expand the cancer therapy pipeline, generate proofs of concept for new innovations, screen for lead products, and reduce research risk before heavily investing in mouse models. ScreenOvo offers cancer cell recognition and killing, tumor infiltration, antibody-dependent cellular cytotoxicity, and checkpoint inhibition.

Funding history · 4 rounds · $160K total

2017-08
Grant Undisclosed
2017-06
Undisclosed
2015-07
Grant Undisclosed
2015-06
Undisclosed

Q&A

What is Innovo Mimetics' primary focus?
Innovo Mimetics specializes in anti-cancer therapy efficacy assays using a chick egg tumor xenograft model.
What is the status of Innovo Mimetics?
Innovo Mimetics is currently inactive, having ceased operations in December 2024.
When was Innovo Mimetics founded?
Innovo Mimetics was founded in March 2010.
What is Innovo Mimetics' proprietary assay system called?
Innovo Mimetics' proprietary assay system is called ScreenOvo.
What are the key advantages of the ScreenOvo Assay?
The ScreenOvo Assay offers a living tumor at low cost, completes an assay in 14 days, and is broadly applicable for testing immune cell therapies, checkpoint inhibition, and anti-cancer drug efficacy.
Who is the founder and CEO of Innovo Mimetics?
Jonathan Goldstein is the Founder & CEO of Innovo Mimetics.
How many employees does Innovo Mimetics have?
Innovo Mimetics has 1-10 employees.
What is the total amount raised by Innovo Mimetics?
Innovo Mimetics has raised a total of $160,000 USD.
When did Innovo Mimetics receive its last grant?
Innovo Mimetics received a grant in August 2017 from the Israel Innovation Authority.

Team · 1

Founder · Founder & CEO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 PatentsVerified

Tags

oncologypharmaceuticalspersonalizationimmunologycancer-researchpharma-companiesservice-providersdrug-discoverycancer
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

Identifiers & details

Founded2010-3
Employees (exact)8
Status reasonNon Active, Dec 2024 ceased to operate